Phase II NESCIO Trial of Neoadjuvant Immunotherapy in Renal Cell Carcinoma - Femke Burgers
Pedro Barata speaks with Femke Burgers about the NESCIO trial, an investigator-initiated phase II study evaluating neoadjuvant immunotherapy in patients with intermediate to high-risk clear cell renal cell carcinoma.
Adjuvant Pembrolizumab Shows Sustained Survival Benefit in Renal Cell Carcinoma at 5 Years - Naomi Balzer-Haas
Naomi Haas
Pedro Barata speaks with Naomi Haas about the KEYNOTE-564 trial, showing sustained overall survival benefit with adjuvant pembrolizumab in clear cell renal cell carcinoma.
